Tianjin Chase Sun Pharmaceutical (300026.SZ): No CRO or CXO Business at the moment.

On December 12, at the investor interaction platform, Tianjin Chase Sun Pharmaceutical (300026.SZ) stated that the main Business it engages in can be roughly divided into Traditional Chinese Medicine granules, finished drugs, medical instruments, raw and auxiliary materials, healthcare services, and intelligent supply chain for drugs and medical devices, with no CRO or CXO Business at present.

Gelonghui FinanceDec 12 16:50

Tianjin Chase Sun Pharmaceutical (300026.SZ): Ibandronate Sodium Injection has passed the consistency evaluation for generic drugs.

On December 12, Gelonghui reported that Tianjin Chase Sun Pharmaceutical (300026.SZ) announced that recently, Tianjin Chase Sun Pharmaceutical Co., Ltd. received the "Pharmaceutical Supplement Application Approval Notice" (Notice No.: 2024B05807, 2024B05808) approved and issued by the National Medical Products Administration. Upon review, Sodium Ibandronate injection passed the consistency evaluation of quality and efficacy for generic drugs, and the supplementary application for the addition of a 2ml:2mg specification was approved, granting a pharmaceutical approval number. Sodium Ibandronate injection is a third-generation bisphosphonate drug developed by Swiss Franc Roche Pharmaceuticals, first introduced in 1996.

Gelonghui FinanceDec 12 16:18

Tianjin Chase Sun Pharmaceutical (300026.SZ): The traditional Chinese medicine industry chain and traditional Chinese medicine diagnosis and treatment service business currently have no presence in xiong'an.

On November 28, Gelonghui reported that tianjin chase sun pharmaceutical (300026.SZ) stated on the investor interaction platform that there is currently no layout for the traditional chinese medicine industry chain and traditional Chinese medicine diagnosis and treatment services business in xiong'an.

Gelonghui FinanceNov 28 18:14

Express News | Tianjin Chase Sun Pharmaceutical: The ketorolac tromethamine injection has passed the consistency evaluation for generic drugs.

BreakingsNov 27 17:18

tianjin chase sun pharmaceutical (300026.SZ): the company's class I innovative lung cancer drug PTS does not involve genetic testing before clinical application.

Gelonghui November 6th | Tianjin Chase Sun Pharmaceutical (300026.SZ) stated on the investor interaction platform that the company's Class I innovative lung cancer drug PTS does not involve genetic testing before clinical application.

Gelonghui FinanceNov 6 16:20

tianjin chase sun pharmaceutical (300026.SZ): No products are involved in this year's medical insurance negotiations.

Gelonghui November 1st, tianjin chase sun pharmaceutical (300026.SZ) stated on the investor interaction platform that the company currently has no products involved in this year's medical insurance negotiations.

Gelonghui FinanceNov 1 16:23